A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Lesions referred to dermatology in the Department of Veterans Affairs (VA) health system: A retrospective chart review Katherine R. Grey, BA, Jaime L.

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle Kathryn.

The impact of chocolate consumption on acne vulgaris in college students: A randomized crossover study Gregory R. Delost, DO, Maria E. Delost, PhD, Jenifer.

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Blaschkoid pityriasis rosea

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Pediatric teledermatology: Observations based on 429 consults

A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo Stefan G. Vanderweil, MD, Shinya.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced.

JAK inhibitors in dermatology: The promise of a new drug class

Assessing adherence with phototherapy protocols

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Smoking and risk of psoriasis: A nationwide cohort study

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis Alice B. Gottlieb, MD, PhD,

Pilot study of a skin cancer education curriculum for medical students

Applying for dermatology residency is difficult and expensive

Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis I.M. Leonie Majoie,

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies Linda.

Reply to: “Comment on ‘Activation of melanocytes in idiopathic guttate hypomelanosis after 5-fluorouracil infusion using a tattoo machine: Preliminary.

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Ivermectin versus permethrin in the treatment of scabies: A systematic review and meta- analysis of randomized controlled trials Ashar Dhana, MBBCh, MPH,

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind,

Infectious rash after riding elephants

Lip edema Journal of the American Academy of Dermatology

Lip and oral mucosal lesions in 100 renal transplant recipients

Serratia marcescens bullous cellulitis after iguana bites

Radhika Grandhi, MPH, Alice He, BS, Yevgeniy R

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

A comparison of postprocedural wound care treatments: Do antibiotic-based ointments improve outcomes? Zoe D. Draelos, MD, FAAD, Ronald L. Rizer, PhD,

Medicaid acceptance among pediatric dermatologists

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial Alice Gottlieb, MD, PhD, John Sullivan,

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Derek Y. Hsu, BA, Kenneth Gordon, MD, Jonathan I

Jose Fernández-Vozmediano, PhD, Jose Armario-Hita, MD

Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Alan Menter, MD, Stephen K

The epidemiology of molluscum contagiosum in children

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Numerous hyperpigmented macules of the oral mucosa

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

“Boot foot” with pseudomonas colonization

Photosensitive lichenoid drug eruption to capecitabine

Reporting of harm and safety results in randomized controlled trials published in 5 dermatology journals Cynthia Haddad, PharmD, MSc, Odette Berline.

Adapalene gel 0.3% for the treatment of acne vulgaris: A multicenter, randomized, double-blind, controlled, phase III trial Diane Thiboutot, MD, David.

Presentation transcript:

A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris Melissa Amy Magliocco, MD, Komal Pandya, MD, RPh, Viktor Dombrovskiy, MD, PhD, MPH, Linda Christiansen, RN, Yuk Wong, RN, BSN, MA, Alice Bendix Gottlieb, MD, PhD Journal of the American Academy of Dermatology Volume 54, Issue 1, Pages 115-118 (January 2006) DOI: 10.1016/j.jaad.2005.09.012 Copyright © 2005 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Participant flow and follow-up. Journal of the American Academy of Dermatology 2006 54, 115-118DOI: (10.1016/j.jaad.2005.09.012) Copyright © 2005 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 A, Target lesion score improvement in drug and placebo groups. (Percent reduction from initial score, mean ± SD.) Left (B) and right (C) posterior forearm target lesion at baseline. D, Left posterior forearm target lesion after drug treatment plus narrowband UVB (NBUVB). Lesion was flat, had minimal scale, and had slight macular erythema secondary to drug. E, Right posterior forearm target lesion after placebo treatment plus NBUVB. Residual scaling, erythema, and induration were present. Journal of the American Academy of Dermatology 2006 54, 115-118DOI: (10.1016/j.jaad.2005.09.012) Copyright © 2005 American Academy of Dermatology, Inc. Terms and Conditions